Cristcot LLC
Drug formulations and integrated drug-device technologies for improved patient adherence and disease management
- Sector
- Biotech
- Headquarters
- CONCORD, MA
- Founded
- 2015
- Latest Form D
- $10.5M, Jun 2025
- Total capital
- $20.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $20.9M
- 4 Form D · last Jun 2025
- 17 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 16
- 12 pending · first 2017
- Rank in peer group#105 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$10.5M
- Private capital raisedForm D · SEC · 3rd filing$7M
- Private capital raisedForm D · SEC · 2nd filing$3M
- Private capital raisedForm D · SEC · 1st filing$411K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#105 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jennifer J. DavagianResearcherExecutive Officer, DirectorLinked by 14 patents
- David H. ShepardDirectorNamed in SEC Form D filings
- David H. ShepherdDirectorNamed in SEC Form D filings
- Ernest H. PomerantzDirectorNamed in SEC Form D filings
- Henry S. KayDirectorNamed in SEC Form D filings
- James Davagian BartlettDirectorNamed in SEC Form D filings
Show all 12 people
- Jennifer Davagian EnsignExecutive Officer, DirectorNamed in SEC Form D filings
- John H. DavagianDirectorNamed in SEC Form D filings
- John S. Davagian IIDirectorNamed in SEC Form D filings
- Marc S. KellerDirectorNamed in SEC Form D filings
- Mark C. EnsignExecutive OfficerNamed in SEC Form D filings
- Richard H. WarburgDirectorNamed in SEC Form D filings
What it has protected
USPTO · 16 granted of 28- PendingMethods Of Treating Gastrointestinal Diseases And DisordersUSPTOApplication 19286557
- GrantedMethods Of Treating Gastrointestinal Diseases And DisordersUSPTOUS 12,396,946
- PendingSuppository Insertion Device, Suppository, And Method Of Manufacturing A SuppositoryUSPTOApplication 19081297
Show all 28 patent records
- Methods Of Treating Gastrointestinal Diseases And DisordersJul 2, 2026 · Application 19286557Pending
- Methods Of Treating Gastrointestinal Diseases And DisordersAug 26, 2025 · US 12,396,946Granted
- Suppository Insertion Device, Suppository, And Method Of Manufacturing A SuppositoryJul 3, 2025 · Application 19081297Pending
- Suppository Insertion Device, Suppository, And Method Of Manufacturing A SuppositoryJul 3, 2025 · Application 19081290Pending
- Suppository Insertion Device, Suppository, And Method Of Manufacturing A SuppositoryJun 24, 2025 · US 12,337,130Granted
- Development And Validation Of The Hemorrhoid Disease Symptom Impact MeasureJun 19, 2025 · Application 19069941Pending
- Single-use Suppository Insertion Device And MethodFeb 13, 2025 · Application 18933111Pending
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseJan 16, 2025 · Application 18887283Pending
- Single-Use Suppository Insertion Device And MethodDec 3, 2024 · US 12,156,984Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseOct 15, 2024 · US 12,115,252Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseOct 15, 2024 · US 12,115,253Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseOct 15, 2024 · US 12,115,251Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseOct 8, 2024 · US 12,109,306Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseSep 24, 2024 · US 12,097,288Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseSep 17, 2024 · US 12,090,226Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseJul 5, 2022 · US 11,376,217Granted
- Single-Use Suppository Insertion Device And MethodApr 12, 2022 · US 11,298,515Granted
- Suppository Insertion Device, Suppository, And Method Of Manufacturing A SuppositoryJan 18, 2022 · US 11,224,727Granted
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseMay 19, 2020 · US 10,653,623Granted
- Method And Apparatus For Inserting A Rectal SuppositoryJan 7, 2020 · US 10,525,242Granted
- Suppository Insertion Device, Suppository, And Method Of Manufacturing A SuppositoryDec 11, 2018 · US 10,149,967Granted
- Method And Apparatus For Inserting A Rectal SuppositoryMay 30, 2017 · US 9,662,481Granted
- Development And Validation Of The Hemorrhoid Disease Symptom Impact MeasureApplication PCTUS2024034869Pending
- Single-use Suppository Insertion Device And MethodApplication PCTUS2017032142Pending
- Methods Of Treating Gastrointestinal Diseases And DisordersApplication 63739846Pending
- Hydrocortisone Acetate Suppository Formulation For Treatment Of DiseaseApplication PCTUS2016021842Pending
- Methods Of Treating Gastrointestinal Diseases And DisordersApplication 63747540Pending
- Methods Of Treating Gastrointestinal Diseases And DisordersApplication PCTUS2025060884Pending
Related companies, and why
- Prevail TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Carbon BiosciencesSimilar federal contract value in Biotech · null in contracts
- Hoth Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Angiex, Inc.Similar federal contract value in Biotech · null in contracts
- SpringWorks TherapeuticsSimilar federal contract value in Biotech · null in contracts
- ALAMAB THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .